Cabozantinib is an oral , small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor ( VEGFR ) as well as MET and AXL , each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs .